TY - JOUR
T1 - Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects :
T2 - A population-based study
AU - Puig Domingo, Manuel
AU - Julián, María Teresa
AU - Ballesta Purroy, Sílvia
AU - Pera, Guillem
AU - Pérez-Montes de Oca, Alejandra
AU - Soldevila i Madorell, Berta
AU - Caballería, Llorenç
AU - Morillas Cunill, Rosa Ma
AU - Expósito, Carmen
AU - Martínez-Escudé, Alba
AU - Franch-Nadal, Josep
AU - Torán, Pere
AU - Cusi, Kenneth
AU - Mauricio Puente, Dídac
AU - Alonso Pedrol, Núria
N1 - Publisher Copyright:
Copyright © 2023 Julián, Ballesta, Pera, Pérez-Montes de Oca, Soldevila, Caballería, Morillas, Expósito, Martínez–Escudé, Puig-Domingo, Franch-Nadal, Torán, Cusi, Julve, Mauricio and Alonso.
PY - 2023/1/13
Y1 - 2023/1/13
N2 - Objective: To investigate longitudinal changes in the liver stiffness measurement (LSM) in the general adult population without known liver disease and to describe its association with metabolic risk factors, with a special focus on subjects with non-alcoholic fatty liver disease (NAFLD) and dysglycemia. Material and Methods: A longitudinal adult population-based cohort study was conducted in Catalonia. LSM was measured by transient elastography (TE) at baseline and follow-up (median: 4.2 years). Subgroup with NAFLD and dysglycemia were analyzed. Moderate-to-advanced liver fibrosis was defined as LSM ≥8.0 kPa and LSM ≥9.2 kPa respectively. Results: Among 1.478 subjects evaluated, the cumulative incidence of LSM ≥8.0 kPa and ≥9.2 kPa at follow-up was 2.8% and 1.9%, respectively. This incidence was higher in NAFLD (7.1% for LSM ≥8.0 kPa and 5% for LSM ≥9.2 kPa) and dysglycemia (6.2% for LSM ≥8.0 kPa and 4.7% for LSM ≥9.2 kPa) subgroups. In the global cohort, the multivariate analyses showed that dysglycemia, abdominal obesity and atherogenic dyslipidemia were significantly associated with progression to moderate-to-advanced liver fibrosis. Female sex was negatively associated. In subjects with NAFLD, abdominal obesity and dysglycemia were associated with changes in LSM to ≥8.0 kPa and ≥9.2 kPa at follow-up. A decline in LSM value to <8 kPa was observed in 64% of those subjects with a baseline LSM ≥8.0 kPa. Conclusions: In this population study, the presence of abdominal obesity and dysglycemia were the main risk metabolic factors associated with moderate-to-advanced liver fibrosis development over time in general populations as well as in subjects with NAFLD.
AB - Objective: To investigate longitudinal changes in the liver stiffness measurement (LSM) in the general adult population without known liver disease and to describe its association with metabolic risk factors, with a special focus on subjects with non-alcoholic fatty liver disease (NAFLD) and dysglycemia. Material and Methods: A longitudinal adult population-based cohort study was conducted in Catalonia. LSM was measured by transient elastography (TE) at baseline and follow-up (median: 4.2 years). Subgroup with NAFLD and dysglycemia were analyzed. Moderate-to-advanced liver fibrosis was defined as LSM ≥8.0 kPa and LSM ≥9.2 kPa respectively. Results: Among 1.478 subjects evaluated, the cumulative incidence of LSM ≥8.0 kPa and ≥9.2 kPa at follow-up was 2.8% and 1.9%, respectively. This incidence was higher in NAFLD (7.1% for LSM ≥8.0 kPa and 5% for LSM ≥9.2 kPa) and dysglycemia (6.2% for LSM ≥8.0 kPa and 4.7% for LSM ≥9.2 kPa) subgroups. In the global cohort, the multivariate analyses showed that dysglycemia, abdominal obesity and atherogenic dyslipidemia were significantly associated with progression to moderate-to-advanced liver fibrosis. Female sex was negatively associated. In subjects with NAFLD, abdominal obesity and dysglycemia were associated with changes in LSM to ≥8.0 kPa and ≥9.2 kPa at follow-up. A decline in LSM value to <8 kPa was observed in 64% of those subjects with a baseline LSM ≥8.0 kPa. Conclusions: In this population study, the presence of abdominal obesity and dysglycemia were the main risk metabolic factors associated with moderate-to-advanced liver fibrosis development over time in general populations as well as in subjects with NAFLD.
KW - Abdominal obesity
KW - Dysglycemia
KW - General population
KW - Liver fibrosis
KW - Nafld
KW - Transient elastography
UR - http://www.scopus.com/inward/record.url?scp=85147103646&partnerID=8YFLogxK
U2 - 10.3389/fendo.2022.1051958
DO - 10.3389/fendo.2022.1051958
M3 - Article
C2 - 36714592
SN - 1664-2392
VL - 13
JO - Frontiers in Endocrinology
JF - Frontiers in Endocrinology
M1 - 1051958
ER -